Jump Financial LLC Has $1.42 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Jump Financial LLC reduced its stake in IQVIA Holdings Inc. (NYSE:IQV) by 78.6% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 7,241 shares of the medical research company’s stock after selling 26,626 shares during the period. Jump Financial LLC’s holdings in IQVIA were worth $1,423,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Synergy Asset Management LLC bought a new position in IQVIA during the 4th quarter worth approximately $33,000. Lee Danner & Bass Inc. bought a new stake in shares of IQVIA in the 4th quarter valued at $44,000. Zions Bancorporation N.A. raised its stake in IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock worth $47,000 after buying an additional 85 shares during the period. Versant Capital Management Inc lifted its holdings in IQVIA by 46.0% during the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock worth $58,000 after acquiring an additional 93 shares in the last quarter. Finally, SBI Securities Co. Ltd. bought a new stake in shares of IQVIA in the fourth quarter worth about $60,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of NYSE IQV opened at $143.66 on Friday. The stock’s fifty day moving average price is $176.42 and its two-hundred day moving average price is $196.62. The firm has a market cap of $25.33 billion, a price-to-earnings ratio of 19.15, a P/E/G ratio of 1.99 and a beta of 1.46. IQVIA Holdings Inc. has a one year low of $135.97 and a one year high of $252.88. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, equities analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Stifel Nicolaus decreased their price objective on IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Barclays reissued an “equal weight” rating and set a $170.00 price objective (down previously from $235.00) on shares of IQVIA in a research report on Thursday, April 10th. BTIG Research cut shares of IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Truist Financial dropped their price target on IQVIA from $263.00 to $216.00 and set a “buy” rating on the stock in a research note on Thursday, April 10th. Finally, UBS Group reduced their price objective on IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Six investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $241.50.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.